Biology subjects

Maslov, D.

Publications and source records attributed to Maslov, D..

3 recordsLinked to original sources

bioRxiv2026

Reconstructing N-Glycan Profiles of Individual Glycoproteins from the Total Blood Plasma N-Glycome: Implications for Immunoglobulin G N-Glycosylation GWAS

The genetic regulation of the plasma N-glycome variation in human populations is not fully characterized, partly due to the limited sample size in glyco-genetics studies. Here, we aimed to demonstrate that protein-specific N-glycan profiles, like those of immunoglobulin G (IgG), can be accurately reconstructed from the total plasma N-glycome (TPNG), enabling us to find new regulators of this complex process re-analysing existing datasets. By testing multiple linear and non-linear machine learning approaches we built a model to reconstruct IgG N-glycans from TPNG data, training on the TwinsUK cohort and validating on CEDAR. We reconstruct GWAS summary statistics for IgG N-glycans by applying the trained linear model to plasma glycan GWAS summary statistics, i.e., as GWAS of linear combinations of plasma glycan traits. The majority of the identified loci had been implicated in IgG N-glycosylation GWAS. Additionally, we found four new loci and suggested the role of FCRLA, KDELR2, HHEX, and TCF3 in the regulation of IgG N-glycosylation. In conclusion, we showed that our method enables the creation of protein-specific N-glycome datasets, allowing for powerful meta-analyses without the need to profile new samples.

genetics↗

bioRxiv2025

Replication of 10 novel loci involved in human plasma protein N-glycosylation using MALDI-MS and UHPLC-FD data

N-glycans are essential components of glycoproteins, influencing their properties and functions. While biochemical pathways of glycosylation are well-characterized, their genetic regulation remains poorly understood. This study utilizes matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) and ultra-high performance liquid chromatography-fluorescence detection (UHPLC-FD) to strengthen replication and further characterize previously identified genome-wide association signals for the total human plasma N-glycome (TPNG). Univariate and multivariate genetic association meta-analyses involved 3,385 samples across 143 N-glycome traits from the Hoorn Diabetes Care System and DiaGene cohorts as well as 3,224 samples across 117 N-glycome traits from TwinsUK, CEDAR, QMDiab and SABRE cohorts. We successfully replicated ten previously identified but not replicated glycosylation quantitative trait loci (glyQTLs) and prioritized five high-confidence putative causal genes, including the glycosyltransferase MGAT4B and inflammation-related genes - C3 and FCGR2B. The linkage-specific sialic acid derivatization in MALDI-MS enabled delineation of genetic effects on 2,3- and 2,6-sialylation. Mass spectrometry analysis also provided evidence for glucuronic acid-containing glycans in human blood plasma. These findings advance our understanding of the genetic regulation of protein N-glycosylation and highlight the complementarity of different analytical approaches in glycomics research.

genetics↗

bioRxiv2018

Mutations in efflux pump Rv1258c (Tap) cause resistance to pyrazinamide and other drugs in M. tuberculosis

Although drug resistance in M. tuberculosis is mainly caused by mutations in drug activating enzymes or drug targets, there is increasing interest in possible role of efflux in causing drug resistance. Previously, efflux genes are shown upregulated upon drug exposure or implicated in drug resistance in overexpression studies, but the role of mutations in efflux pumps identified in clinical isolates in causing drug resistance is unknown. Here we investigated the role of mutations in efflux pump Rv1258c (Tap) from clinical isolates in causing drug resistance in M. tuberculosis by constructing point mutations V219A, S292L in Rv1258c in the chromosome of M. tuberculosis and assessed drug susceptibility of the constructed mutants. Interestingly, V219A, S292L point mutations caused clinically relevant drug resistance to pyrazinamide (PZA), isoniazid (INH), and streptomycin (SM), but not to other drugs in M. tuberculosis. While V219A point mutation conferred a low level resistance, the S292L mutation caused a higher level of resistance. Efflux inhibitor piperine inhibited INH and PZA resistance in the S292L mutant but not in the V219A mutant. S292L mutant had higher efflux activity for pyrazinoic acid (the active form of PZA) than the parent strain. We conclude that point mutations in the efflux pump Rv1258c in clinical isolates can confer clinically relevant drug resistance including PZA and could explain some previously unaccounted drug resistance in clinical strains. Future studies need to take efflux mutations into consideration for improved detection of drug resistance in M. tuberculosis and address their role in affecting treatment outcome in vivo.

microbiology↗